On April 13th, 2017, China Food and Drug Administration (CFDA) Center for Drug Evaluation (CDE) announced the fifteenth batch of candidates for new drug applications and their applicants. Among these applicants, Kawin Technology has its classification 1 pegylated recombinant census interferon variant injection, i.e., long-acting interferon selected as a candidate for priority review due to the significant benefit over China’s anti-HCV standard-of-care in current use.